Oct 27, 2016 at 09:47 | Source: Moneycontrol.com
CLSA cuts FY17-19 EPS by 1-2 percent but revised target to Rs 930 per share from Rs 885 per share and upgraded to outperform. The management is fairly confident of a gradual recovery ahead.
Oct 19, 2016 at 11:42 | Source: Moneycontrol.com
BHEL shares surged 5.4 percent intraday Wednesday, in addition to 3.3 percent rally in previous session after CLSA upgraded the stock to buy from sell on improved EPS visibility on the legal victory by its client Tamil Nadu Generation and Distribution Corporation (TANGEDCO) in Ennore project.
Oct 14, 2016 at 11:33 | Source: Moneycontrol.com
Deutsche Bank maintains buy rating on the stock with a revised target price of Rs 2900 stating that project delays hurt revenue growth but margin beat a big positive. Given macroeconomic headwinds, it assumes a conservative stance and now expects TCS to deliver 7.1 percent YoY USD revenue growth with EPS of Rs 135.6.
Oct 14, 2016 at 08:48 | Source: Moneycontrol.com
Citi has a sell rating on TCS and slashed target price to Rs 2155 per share from Rs 2315 per share. It has also lowered FY17/18 EPS estimate by 1/2 percent. It says demand outlook remains challenged with multiple headwinds.
Oct 10, 2016 at 09:00 | Source: Moneycontrol.com
Credit Suisse maintains neutral rating on Glenmark due to high profit concentration in Mupirocin as upside risk exists from out-licensing opportunity from innovative R&D pipeline. Mupirocin cream accounts for 18 percent of FY18 EPS, as risk of competition is high.
Oct 06, 2016 at 09:00 | Source: CNBC-TV18
We have prepared our estimates under Ind-AS, though Q2FY16 results are under I-GAAP. We calculate BSE-30 Index's FY17e EPS at Rs 1,479 and FY18e EPS at Rs 1,792, says Sanjeev Prasad of Kotak Institutional Equities.
Oct 05, 2016 at 10:33 | Source: CNBC-TV18
Credit Suisse' Neelkanth Mishra expects repo rate to fall to a decade low in the coming quarters. He says that beginning December the market may see a robust and widespread pick-up which may boost indices.
Sep 27, 2016 at 14:00 | Source: Moneycontrol.com
UBS has also cut FY17/FY18/FY19 earnings per share (EPS) estimates by 15/17/15 percent as incorporating its disappointing Q1 results. It expects a structural shift in Just Dials EBITDA margins as it grows further in the Tier 2-3 cities.
Sep 20, 2016 at 16:00 | Source: Moneycontrol.com
The burden on Ashok Leyalnd's EPS and valuation will be felt by the minor investors post this merger as short term gains are nowhere to be seen.
Sep 20, 2016 at 10:02 | Source: Moneycontrol.com
Bank of America Merrill Lynch (BoAML) has maintained its buy rating on Aurobindo Pharma on expectations of strong 23 percent earnings per share (EPS) CAGR over FY16-18, especially after USFDA's successful inspection of unit IV plant at Andhra Pradesh and establishment inspection report for Penem facilities.